tbuckley/cabot-search huggingface dataset:
Advancing the Health of Lesbian, Gay, and Bisexual Adults—Reply
Authors: Gilbert Gonzales, Carrie Henning-Smith, Julia Przedworski
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Characterization of a novel intrinsically radiopaque Drug-eluting Bead for image-guided therapy: DC Bead LUMI™
Authors: Koorosh Ashrafi, Yiqing Tang, Hugh Britton, Orianne Domenge, Delphine Blino, Andrew J. Bushby, Kseniya Shuturminska, Mark den Hartog, Alessandro Radaelli, Ayele H. Negussie, Andrew S. Mikhail, David L. Woods, Venkatesh Krishnasamy, Elliot B. Levy, Bradford J. Wood, Sean L. Willis, Matthew R. Dreher, Andrew L. Lewis
Journal: Journal of Controlled Release (2017)

We have developed a straightforward and efficient method of introducing radiopacity into Polyvinyl alcohol (PVA)-2-Acrylamido-2-methylpropane sulfonic acid (AMPS) hydrogel beads (DC Bead™) that are currently used in the clinic to treat liver malignancies. Coupling of 2,3,5-triiodobenzaldehyde to the PVA backbone of pre-formed beads yields a uniformly distributed level of iodine attached throughout the bead structure (~ 150 mg/mL) which is sufficient to be imaged under standard fluoroscopy and computed tomography (CT) imaging modalities used in treatment procedures (DC Bead LUMI™). Despite the chemical modification increasing the density of the beads to ~ 1.3 g/cm3 and the compressive modulus by two orders of magnitude, they remain easily suspended, handled and administered through standard microcatheters. As the core chemistry of DC Bead LUMI™ is the same as DC Bead™, it interacts with drugs using ion-exchange between sulfonic acid groups on the polymer and the positively charged amine groups of the drugs. Both doxorubicin (Dox) and irinotecan (Iri) elution kinetics for all bead sizes evaluated were within the parameters already investigated within the clinic for DC Bead™. Drug loading did not affect the radiopacity and there was a direct relationship between bead attenuation and Dox concentration. The ability (Dox)-loaded DC Bead LUMI™ to be visualized in vivo was demonstrated by the administration of into hepatic arteries of a VX2 tumor-bearing rabbit under fluoroscopy, followed by subsequent CT imaging.
Disease Specific Modulation of Serum Hepcidin: Impact of GDF-15 and Iron Metabolism Markers in Thalassemia Major, Thalassemia Intermedia and Sickle Cell Disease: A Univariate and Multivariate Analysis.
Authors: Farzana Sayani, Sukhvinder Bansal, Patricia Evans, Aalim Weljie, Robert C Hider, John B Porter
Journal: Blood (2008)
Blood Cadmium and C-Reactive Protein Levels As Risk Factors for Allergic and Respiratory Diseases in Early Childhood: The Mothers and Children's Environmental Health Study
Authors: Ja Hyeong Kim, Eun-Hee Ha, Hyesook Park, Mina Ha, Yun-Chul Hong, Jin-A. Jung, Yangho Kim
Journal: Journal of Allergy and Clinical Immunology (2017)
KOC (K homology domain containing protein overexpressed in cancer) overexpression and progression-free survival after curative intent resection of pancreatic ductal adenocarcinoma.
Authors: Benny Johnson, Maged F. Khalil, Fan Lin, Shaobo Zhu, Lester Kirchner
Journal: Journal of Clinical Oncology (2012)

48 Background: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality in the United States. Unfortunately, effective screening and early detection mechanisms are currently unavailable, thereby 80% of patients present with distant metastasis. Of the subset of patients eligible for curative intent surgery, the 5-year survival rate is only 20%. Negative surgical margins, tumor size, stage, and node negative disease are traditional prognostic indicators. However, these can be limited in their ability to predict patient specific prognosis. KOC is an oncofetal RNA-binding protein involved in RNA stabilization and cell growth during embryogenesis. Previous studies have revealed that KOC mRNA is inappropriately overexpressed in pancreatic cancer and that increased expression correlates with tumor stage. In this study, we attempt to identify whether KOC expression in patients who undergo curative intent surgery correlates with progression free survival. Methods: Tissue microarrays prepared from formalin-fixed, paraffin-embedded specimens of patients with PDAC who underwent curative intent surgery were assessed by immunohistochemistry. Results: A total of 35 patients were included. Comparisons between groups on progression free survival are estimated using the Kaplan-Meier method and the log-rank test. KOC was overexpressed in 23.6% of tumors. It was found that there were zero patients with a high KOC expression and no distant metastasis. Patients with a high KOC expression were more than 3 times more likely to progress compared to those with a low KOC expression (HR=3.54, 95% CI: 1.34, 9.36, p=0.011). Conclusions: KOC is a useful prognostic biomarker for predicting those patients with PDAC who have a high risk for early progression and distant metastasis. Identifying patients with high KOC expression upon initial diagnosis can serve as a way to risk stratify patients to aggressive treatment regimens upfront and early exposure to clinical trials.
Epigallocatechin-3-Gallate (EGCG) Modulates Cytokine Production When Leukemic CLL B-Cells and Marrow Stromal Cells Are Co-Cultured: Correlations with Clinical Activity in a Phase II Trial,
Authors: Connie Lesnick, Neil Kay, Betsy R. LaPlant, Asish K Ghosh, Tait D. Shanafelt
Journal: Blood (2011)
Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome
Authors: Hawk Kim, Je-Hwan Lee, Won-Sik Lee, Inho Kim, Joon Ho Moon, Chul Won Choi, Ho Sup Lee, Jinny Park, Ho-Jin Shin, Kyoung Ha Kim, Su-Hee Cho, Sung-Yong Kim, Yoo-Jin Kim
Journal: Blood (2015)
Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens
Authors: Cindy S. Chu, Germana Bancone, Kerryn A. Moore, Htun Htun Win, Niramon Thitipanawan, Christina Po, Nongnud Chowwiwat, Rattanaporn Raksapraidee, Pornpimon Wilairisak, Aung Pyae Phyo, Lily Keereecharoen, Stéphane Proux, Prakaykaew Charunwatthana, François Nosten, Nicholas J. White
Journal: PLoS Medicine (2017)

Background Radical cure of Plasmodium vivax malaria with 8-aminoquinolines (primaquine or tafenoquine) is complicated by haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD heterozygous females, because of individual variation in the pattern of X-chromosome inactivation (Lyonisation) in erythroid cells, may have low G6PD activity in the majority of their erythrocytes, yet are usually reported as G6PD “normal” by current phenotypic screening tests. Their haemolytic risk when treated with 8-aminoquinolines has not been well characterized. Methods and Findings In a cohort study nested within a randomised clinical trial that compared different treatment regimens for P. vivax malaria, patients with a normal standard NADPH fluorescent spot test result (≳30%–40% of normal G6PD activity) were randomised to receive 3 d of chloroquine or dihydroartemisinin-piperaquine in combination with primaquine, either the standard high dose of 0.5 mg base/kg/day for 14 d or a higher dose of 1 mg base/kg/d for 7 d. Patterns of haemolysis were compared between G6PD wild-type and G6PD heterozygous female participants. Between 21 February 2012 and 04 July 2014, 241 female participants were enrolled, of whom 34 were heterozygous for the G6PD Mahidol variant. Haemolysis was substantially greater and a larger proportion of participants reached the threshold of clinically significant haemolysis (fractional haematocrit reduction >25%) in G6PD heterozygotes taking the higher (7 d) primaquine dose (9/17 [53%]) compared with G6PD heterozygotes taking the standard high (14 d) dose (2/16 [13%]; p = 0.022). In heterozygotes, the mean fractional haematocrit reductions were correspondingly greater with the higher primaquine dose (7-d regimen): −20.4% (95% CI −26.0% to −14.8%) (nadir on day 5) compared with the standard high (14 d) dose: −13.1% (95% CI −17.6% to −8.6%) (nadir day 6). Two heterozygotes taking the higher (7 d) primaquine dose required blood transfusion. In wild-type participants, mean haematocrit reductions were clinically insignificant and similar with both doses: −5.8 (95% CI −7.2% to −4.4%) (nadir day 3) compared with −5.5% (95% CI −7.4% to −3.7%) (nadir day 4), respectively. Limitations to this nested cohort study are that the primary objective of the trial was designed to measure efficacy and not haemolysis in relation to G6PD genotype and that the heterozygote groups were small. Conclusion Higher daily doses of primaquine have the potential to cause clinically significant haemolysis in G6PD heterozygous females who are reported as phenotypically normal with current point of care tests. Trial Registration ClinicalTrials.gov NCT01640574.
Freeze-Dried Platelet Rich Plasma (PRP) Has Biological Activity in Acute Wound Healing of Animals, Inducing Significantly Angiogenesis
Authors: Stephany Cares Huber, Silmara Aparecida De Lima Montalvão, Letícia Queiroz da Silva, José Luiz Rosenberis Cunha Junior, Erich Vinicius De Paula, Joyce Maria Annichino-Bizzacchi
Journal: Blood (2016)
Nivolumab induced myxedema crisis
Authors: Uqba Khan, Humaira Rizvi, Dahlia Sano, Jane Chiu, Tarik Hadid
Journal: Journal for ImmunoTherapy of Cancer (2017)

Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that is approved by Food and Drug Administration for treatment of metastatic non-small cell lung cancer, metastatic melanoma, relapsed Hodgkin lymphoma and advanced renal cell cancer. We report a rare case of myxedema crisis induced by nivolumab in a patient with metastatic squamous cell carcinoma of lung.Fifty three-year old woman with metastatic squamous cell carcinoma currently on treatment with nivolumab presented with diffuse facial and tongue swelling, slurred speech, depressed mentation, fatigue and weakness. Initial evaluation revealed severe hypothyroidism with thyroid stimulating hormone of 237 micro Unit/mL (Normal Reference range: 0.27-4.20 micro unit/mL) and undetectable free T4. Patient was diagnosed with nivolumab induced myxedema crisis. She was treated successfully with levothyroxine with complete resolution of her symptoms. Nivolumab was safely restarted once the symptoms of myxedema resolved.Nivolumab can cause immune-mediated endocrinopathies including thyroiditis, hypophysitis, adrenal insufficiency and type 1 diabetes mellitus. High index of suspicion and periodic measurement of thyroid function tests are recommended in patients receiving nivolumab therapy. Our case also suggests that once the myxedema crisis is treated and symptoms are resolved, nivolumab can be safely re-challenged.
Ad-ISF35-Transduced Autologous Cells Promote in Vitro and In Vivo Chemosensitization to FCR in Patients with Del(17p) / P53 Defective Chronic Lymphocytic Leukemia.
Authors: Januario E. Castro, Johanna Melo-Cardenas, Jose Sandoval-Sus, Mauricio Urquiza, Charles Prussak, Thomas J. Kipps
Journal: Blood (2009)
Genome-Wide Array-Based Methylation Profiling Reveals Preferential Methylation of Homeobox Transcription Factor Genes In Mantle Cell Lymphoma and Pro-Apoptotic Genes In Chronic Lymphocytic Leukemia
Authors: Anna M Halldorsdottir, Meena Kanduri, Millaray Marincevic, Hanna Göransson, Anders Isaksson, Mahmoud Mansouri, Kostas Stamatopoulos, Birgitta Sander, Hans Ehrencrona, Richard Rosenquist
Journal: Blood (2010)
The Addition of Fludarabine to a Conventional Busulfan/Melphalan/Anti-Thymocyte Globulin (Flu/Bu/Mel/ATG) Preparative Regimen Increased Engraftment without Additional Toxicity.
Authors: Sonali Lakshminarayanan, Adam Mendizabal, Vinod Prasad, Suhag Parikh, Paul Szabolcs, Timothy Driscoll, Michelle Schweitzer, Barbara Kassmann, Mary Paden, Danielle Robinette, Paul L. Martin, Joanne Kurtzberg
Journal: Blood (2006)
Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse
Authors: Nicola Goekbuget, Daniel Stanze, Renate Arnold, Monika Brueggemann, Rainer Fietkau, Mathias Freund, Arnold Ganser, Wolf-Dieter Ludwig, Georg Maschmeyer, Thorsten Raff, Harald Rieder, Eckhard Thiel, Hubert Serve, Michael Kneba, Dieter Hoelzer
Journal: Blood (2011)
Improving Antibiotic Choice in Hospitalized Medical Patients Reporting Penicillin Allergy
Authors: Kimberly G. Blumenthal, Paige G. Wickner, Shelley Hurwitz, Nicholas Pricco, Alexandra E. Nee, Karl Laskowski, Erica S. Shenoy, Rochelle P. Walensky
Journal: Journal of Allergy and Clinical Immunology (2017)
Randomized phase II trial of NGR-hTNF in combination with standard chemotherapy in previously untreated non-small cell lung cancer (NSCLC).
Authors: Vanesa Gregorc, Nicoletta Zilembo, Francesco Grossi, Tommaso M De Pas, Gilda Rossoni, Filippo Pietrantonio, Erika Rijavec, Giovanni Citterio, Antonio Lambiase, Claudio Bordignon
Journal: Journal of Clinical Oncology (2013)

8035 Background: NGR-hTNF, a selective antivascular agent, induces at low dose an initial vascular normalization that greatly enhances the intratumoral chemotherapy uptake, with synergistic effects that were noted especially in combination with cisplatin and gemcitabine. Methods: Chemo-naive patients (pts) with advanced NSCLC were stratified by histology (nonsquamous or squamous) and PS (0 or 1) and randomly assigned to receive cisplatin 80 mg/m 2 /d1 plus either pemetrexed 500 mg/m 2 /d1 (nonsquamous) or gemcitabine 1,250 mg/m 2 /d1+8 (squamous) every 3 weeks (q3w) for 6 cycles, with (arm A) or without (arm B) NGR-hTNF given at 0.8 μg/m 2 /d1/q3w until progression. Progression-free survival (PFS) was primary aim (1-β=80%, 1-sided α=10%, n=102). Secondary aims comprised adverse events (AEs), response rate (RR), and overall survival (OS). Results: Baseline characteristics in arm A (n=62) vs B (n=59) were: median age: 62 vs 63 years; men: 37 vs 39; PS 1: 23 vs 23; squamous: 18 v 17; smokers: 41 vs 43. For the nonsquamous stratum, 299 cycles were given in arm A (mean 7.0; range 1-20) and 192 in arm B (4.8; 1-6), while for the squamous stratum, 113 in arm A (6.7; 1-31) and 52 in arm B (3.5; 1-6). Rates of grade 3/4 AEs were similar (arm A vs B): neutropenia 13% vs 18%, anaemia 7% vs 4% and fatigue 7% vs 11%. No grade 3/4 AEs related to NGR-hTNF or bleeding/pulmonary hemorrhage events were reported in the squamous subset. With median follow-up time of 24.2 months, median PFS (5.8 vs 5.6 months; HR=0.92), RR (25% vs 21%) and 1-year OS (53% vs 53%) were similar between the two treatment arms. However, by predefined analysis in the squamous stratum, median PFS was 5.6 months for arm A and 4.3 months for arm B (hazard ratio, HR=0.75) and median OS was 14.2 months for arm A and 9.7 months for arm B (HR=0.49; p=0.07). In pts with squamous histology, RR was 38% for arm A and 27% for arm B (odds ratio=1.6), while the median changes in tumor size on treatment from baseline to 2nd, 4th and 6th cycle for arm A vs B were -32% vs -20%, -41% vs -19%, and -42% vs -14%, respectively. Conclusions: Clinical tolerability and benefit were noted in squamous NSCLC with NGR-hTNF plus cisplatin and gemcitabine, which deserve further investigation. Clinical trial information: NCT00994097.
Clinical Characteristic and Prognosis of Post-Transplant Lymphoproliferative Disorder in Pediatric Heart Transplant Recipients in Japan
Authors: Takako Miyamura, Yoshiko Hashii, Norihide Fukushima, Shigetoyo Kogaki, Hisao Yoshida, Kunihiko Takahashi, Jun Narita, Keiichi Ozono
Journal: Blood (2015)
Ex Vivo Expansion of Human Mobilized Peripheral Blood Stem Cells Using Epigenetic Modifiers
Authors: Santosh Saraf, Hiroto Araki, Benjamin Petro, Kazumi G Yoshinaga, Simona Taioli, Amer Sidani, John G. Quigley, Damiano Rondelli, Nadim Mahmud
Journal: Blood (2011)
P06.15 IFI16 expression in gliomas and its potential role in immunosurveillance
Authors: B. Pollo, J. Mazibrada, C. Calatozzolo, F. Cacciatore, S. Spinello, V. Girgenti, F. Sciacca, G. Finocchiaro, S. Landolfo, M. Patanè
Journal: Neuro-Oncology (2016)
Decreased Expression of Indoleamine 2,3-Dioxygenase 1 (IDO 1) in Dendritic Cells From Patients with Immune Thrombocytopenia (ITP) Correlates with Impaired Regulatory T Cells Development
Authors: Lucia Catani, Daria Sollazzo, Antonio Curti, Sara Trabanelli, Cecilia Evangelisti, Francesca Palandri, Nicola Polverelli, Michele Baccarani, Nicola Vianelli, Roberto M. Lemoli
Journal: Blood (2010)
Intestinal commensal bacteria mediate lung mucosal immunity and promote resistance of newborn mice to infection
Authors: Jerilyn Gray, Katherine Oehrle, George Worthen, Theresa Alenghat, Jeffrey Whitsett, Hitesh Deshmukh
Journal: Science Translational Medicine (2017)

Postnatal colonization by intestinal commensal bacteria directs migration of innate lymphoid cells to the lungs and promotes resistance of newborn mice to pneumonia.
RARE-23. PATTERNS OF CARE AND SURVIVAL OUTCOMES IN PATIENTS WITH EXTRA VENTRICULAR: AN INDIVIDUAL PATIENT DATA ANALYSIS
Authors: Supriya Mallick, Rony Benson, Goura Kishor Rath, Pramod Julka
Journal: Neuro-Oncology (2016)

Extra ventricular Neurocytoma (EVN) is extremely rare with less than 200 cases reported so far in literature. We performed PubMed search with following MesH terms: “neurocytoma, neurocytoma extra-ventricular” to find all possible publications pertaining to EVN. Individual patient data on “age, gender, type of surgery, radiation, recurrence, and survival” were tabulated. Data was analyzed with SPSS version 16. A total of 193 cases from 157 publications were eligible for the analysis. Median age was 28 years (0.6-78 years). Male: female ratio of 1.04:1. 25% of the patients had tumor in the frontal lobe followed by 17%, 11%,11% in temporal, parietal,and Thoracic spine. 9% had disease in cervical spine, 6% in brainstem and 4% in cerebellum. Presenting symptoms were available for 80 patients; seizure was commonest in 35%, followed by headache in 31%. Surgical details were available for 114 cases and 50% underwent gross total resection while 43.8% underwent a subtotal resection, 6% biopsy alone. Median MIB labeling index was 5 (range: 1-60). Median follow up was 17 months (Range 1-120). The median progression free survival (PFS) was 66 months. Median PFS was 140 months for younger patients (<20 years) vs 30 months (>20 years); p=0.043. Patients with a cerebral primary had a PFS of 180 months vs. 24 months for spinal EVN; p=0.003. A higher MIB labelling index of more than 8% had a trend towards worse PFS 72 m Vs. 14 m; p=0.089. However, univariate analysis revealed gender, type of surgery, and use of adjuvant radiation to be significant factors affecting survival. EVN is a very rare tumor. Most common site of tumor is frontal lobe. PFS is significantly better for younger patients with disease inside cerebrum and MIB labelling index <8%. However, extent of surgery and adjuvant radiation had no impact on survival.
65PD Significance of preoperative fine-needle aspiration biopsy for suspected cases of lymph node metastasis in primary breast cancer
Authors: A. Ogiya, T. Iwase, N. Teruya, H. Sakamoto, E. Nakashima, A. Kataoka, D. Kitagawa, T. Sakai, H. Morizono, Y. Miyagi, R. Horii, F. Akiyama, S. Ohno
Journal: Annals of Oncology (2016)
Comparison of YM150, an Oral, Direct Factor Xa Inhibitor, with Other Antithrombotic Agents in Rodent Venous and Arterial Thrombosis Models.
Authors: Minori Saitoh, Seiji Kaku, Toshiyuki Funatsu, Hiroyuki Koshio, Tsukasa Ishihara, Fukushi Hirayama, Tomihisa Kawasaki, Masao Sasamata
Journal: Blood (2007)
Disruption of STAT3 Signaling in Antigen Presenting Cells Represents a Novel Strategy To Overcome Tumor-Induced Antigen-Specific CD4+ T-Cell Tolerance.
Authors: Fengdong Cheng, Hongwei Wang, Alex G. Cuenca, Pedro Horna, Lldefonso Suarez, Jason Brayer, James Turkson, Richard Jove, Eduardo M. Sotomayor
Journal: Blood (2004)
Tifab, a Novel Candidate Gene in Deletion Chromosome 5q, Contributes to Deregulation of NF-κB Signaling in MDS/AML.
Authors: Melinda Varney, Andres Jerez, Jing Fang, David Miller, Lyndsey Bolanos, Aly Karsan, Jaroslaw P. Maciejewski, Daniel T Starczynowski
Journal: Blood (2012)
Outcome of second-line treatment (2L Tx) following <i>nab</i>-paclitaxel (<i>nab</i>-P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC).
Authors: David Goldstein, E. Gabriela Chiorean, Josep Tabernero, Robert Hassan El-Maraghi, Wen Wee Ma, Michele Reni, Marion Harris, Robert C. Whorf, Susan Coughlin, Jack Li, Victoria G. Manax, Brian D. Lu, Alfredo Romano, Daniel D. Von Hoff
Journal: Journal of Clinical Oncology (2016)

333 Background: The impact of 2L Tx in MPC is not well described. The phase III MPACT trial (N = 861) demonstrated superior efficacy for nab-P + G vs G alone for 1L Tx of MPC. This post hoc analysis examined 2L Tx use in pts in MPACT. Methods: OS was estimated by the Kaplan-Meier method, using the most updated information from MPACT. Data were summarized by type of 2L Tx. Results: 347 pts received 2L Tx. Baseline characteristics (at start of 1L) of those pts were balanced between arms and representative of the ITT population: median age, 61-62 years; 12% had &gt; 3 metastatic sites, and ≈ 30% had Karnofsky PS 70-80 in each arm. 26% and 14% of pts in the nab-P + G and G arms, respectively, discontinued 1L Tx for adverse events. OS in the 347 pts was significantly longer for nab-P + G vs G (Table). The median time from the end of 1L Tx to death for pts receiving no 2L Tx was 2.5 and 1.6 mo in the nab-P + G and G arms, respectively (HR, 0.67; P &lt; 0.001), less than half for those who received any 2L Tx (5.3 and 4.5 mo). 78% and 76% of pts received a 5FU/capecitabine (cape)–containing regimen as 2L Tx after nab-P + G and G and achieved 13.5 and 9.5 mo of median OS, respectively. Conclusions: 2L Tx after nab-P + G or G alone in MPC is feasible and may potentially improve pt outcomes. Clinical trial information: NCT00844649. [Table: see text]
Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.
Authors: Giovanni Martinelli, Daniela Cilloni, Michela Rondoni, Francesca Messa, Emanuela Ottaviani, Enrico Gottardi, Pier Paolo Piccaluga, Michele Malagola, Simona Soverini, Serena Merante, Giuliana Alimena, Costanza Bosi, Antonio De Vivo, Gianantonio Rosti, Emilia Giugliano, Fabrizio Pane, Barbara Izzo, Nicoletta Testoni, Stefania Paolini, Francesca Rancati, Renato Bassan, Cristina Mecucci, Michele Baccarani, Giuseppe Saglio
Journal: Blood (2005)